Impact of Pharmacogenomics on Warfarin Dosing Among Egyptian Patients
/ 0
- Details
- Category: Vol. 84, December 2016
- Hits: 684
Impact of Pharmacogenomics on Warfarin Dosing Among Egyptian Patients, AHMED A.H. AHMED, MANAL E. ABO-FARHA, SHERIF N. AMIN and MAHA F. YOUSSEF
Abstract
Aim of the Study: Screen a random sample of Egyptian patients for genetic polymorphism affecting warfarin and correlating them to warfarin dosing.
Methods: Twenty-eight patients candidates for anticoag-ulation with warfarin are screened for Single Nucleotide Polymorphism (SNPs) known to affect warfarin pharmacok-inetics, then correlating the genetic pattern with the mean INR and the needed Median warfarin dose.
Results: VKORC1 mutation increases the required dose of warfarin to attain a target INR in Egyptian population homozygous (AA) more than heterozygous (GA) variant. CYP4502C9 mutations decrease the required dose of warfarin to achieve a target INR in Egyptian population homozygous (3*/3*) more than heterozygous (1*/2* and 1*/3*) alleles even though, the difference is marginal.
Conclusion: Pharmacogenomic testing marginally im-proves initial warfarin dosing. This may be beneficial in high risk patients.